[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338122-105":59,"doc-detail-338122-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","parp-inhibition-with-rucaparib-alone-followed-by-combination-with-atezolizumab-phase-ib-couplet-clinical-study-in-advanced-gynaecological-and-triple-negative-breast-cancers","PARP inhibition with rucaparib alone followed by combination with atezolizumab - Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers","","Combining PARP inhibitors with immune checkpoint inhibitors may enhance outcomes in selected cancers. This Phase Ib COUPLET study evaluated rucaparib followed by combination with atezolizumab in advanced gynaecological cancers or triple-negative breast cancer (TNBC). After the recommended dose was established, PARPi-naive patients with BRCA-mutated or HRD/loss-of-heterozygosity-high platinum-sensitive ovarian cancer or TNBC received rucaparib plus atezolizumab. Tumour biopsies were collected pre-treatment, during rucaparib monotherapy, and after combination start.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/parp-inhibition-with-rucaparib-alone-followed-by-combination-with-atezolizumab-phase-ib-couplet-clinical-study-in-advanced-gynaecological-and-triple-negative-breast-cancers/338122/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/parp-inhibition-with-rucaparib-alone-followed-by-combination-with-atezolizumab-phase-ib-couplet-clinical-study-in-advanced-gynaecological-and-triple-negative-breast-cancers/338122.png","ImageObject",300,407,{"name":92,"@type":93},"Theodore","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main purpose of the COUPLET Phase Ib study?","Question",{"text":112,"@type":113},"To evaluate rucaparib and atezolizumab, first with rucaparib alone and then as a combination, in advanced gynaecological cancers and triple-negative breast cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Who were the participants and what treatments did they receive?",{"text":117,"@type":113},"After dose identification, patients with PARPi-naive BRCA-mutated or HRD/loss-of-heterozygosity-high platinum-sensitive ovarian cancer or TNBC received rucaparib plus atezolizumab.",{"name":119,"@type":110,"acceptedAnswer":120},"What adverse events were most common during the study?",{"text":121,"@type":113},"The most common adverse events included gastrointestinal effects, fatigue, liver enzyme elevations, and anaemia.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338122,1790470493,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},7971461740886,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","[www.nature.com/bjc](www.nature.com/bjc British)[ British](www.nature.com/bjc British) Journal of Cancer  \nARTICLE OPEN   \nClinical Studies  \nPARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers  \nRebecca Kristeleit 1,2,16 ✉, Alexandra Leary3, Ana Oaknin 4, Andres Redondo5, Angela George6,7, Stephen Chui8, Aicha Seiller9, Mario Liste-Hermoso9, Jenna Willis10, Colby S. Shemesh 11, Jim Xiao12, Kevin K. Lin12, Luciana Molinero 13, Yinghui Guan13, Isabelle Ray-Coquard 14 and Linda Mileshkin 15  \n© The Author(s) 2024  \n\n|  | BACKGROUND: Combining PARP inhibitors (PARPis) with immune checkpoint inhibitors may improve clinical outcomes in selected cancers. We evaluated rucaparib and atezolizumab in advanced gynaecological or triple-negative breast cancer (TNBC) . METHODS: After identifying the recommended dose, patients with PARPi-naive BRCA-mutated or homologous recombinationdeﬁcient/loss-of-heterozygosity-high platinum-sensitive ovarian cancer or TNBC received rucaparib plus atezolizumab. Tumour biopsies were collected pre-treatment, during single-agent rucaparib run-in, and after starting combination therapy.\u003Cbr>RESULTS: The most common adverse events with rucaparib 600 mg twice daily and atezolizumab 1200 mg on Day 1 every 3 weeks were gastrointestinal effects, fatigue, liver enzyme elevations, and anaemia. Responding patients typically had BRCA-mutated tumours and higher pre-treatment tumour levels of PD-L1 and CD8 + T cells. Markers of DNA damage repair decreased during rucaparib run-in and combination treatment in responders, but typically increased in non-responders. Apoptosis signature expression showed the reverse. CD8 + T-cell activity and STING pathway activation increased during rucaparib run-in, increasing further with atezolizumab.\u003Cbr>CONCLUSIONS: In this small study, rucaparib plus atezolizumab demonstrated acceptable safety and activity in BRCA-mutated tumours. Increasing anti-tumour immunity and inﬂammation might be a key mechanism of action for clinical beneﬁt from the combination, potentially guiding more targeted development of such regimens |  |\n| --- | --- | --- |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| .\u003Cbr>CLINICAL TRIAL REGISTRATION: [ClinicalTrials.gov](ClinicalTrials.gov) (NCT03101280). |  |  |\n|  | British Journal of Cancer (2024) 131:820–831; [https://doi.org/10.1038/s41416-024-02776-7](https://doi.org/10.1038/s41416-024-02776-7) |  |\n|  |  |  |\n\nBACKGROUND  \nThe treatment landscape in gynaecological cancers and triplenegative breast cancer (TNBC) has changed substantially in recent years. Poly(ADP-ribose) polymerase (PARP) is a validated target for ovarian cancer and TNBC, especially for patients with homologous recombination deﬁciency (HRD), including loss-of-function mutations on BRCA1, BRCA2, and other genes important for DNA damage repair (DDR) and genomic loss of heterozygosity (gLOH) . Following single-or double-strand DNA breaks, PARP is rapidly recruited to the damaged sites, signalling other DDR effector proteins to repair the damage. PARP inhibitors (PARPis) block the recruitment of effector  \nproteins and DDR, and also (to varying degrees according to the agent) trap PARP at the DNA replication fork to block transcription and translation [1, 2] . In patients with HRD tumours, PARPis can induce synthetic lethality leading to decreased DDR, cell cycle arrest, and apoptosis [3] . PARPis have become part of standard therapy, initially as maintenance for platinum-sensitive recurrent ovarian cancer [4–6], and now in the front-line maintenance setting for ovarian cancer (with or without anti-angiogenic therapy) [7–9] . PARPis are also part of standard therapy in pre-treated metastatic BRCA-mutated breast cancer [10, 11] and as adjuvant therapy for BRCA-mutated early breast canc","cbCairNXB2g6DZfC","https://ap.wps.com/l/cbCairNXB2g6DZfC","pdf",2293344,12,"English","# Background\n# Methods\n# Results\n# Conclusions\n# Clinical trial registration","[{\"question\":\"What was the main purpose of the COUPLET Phase Ib study?\",\"answer\":\"To evaluate rucaparib and atezolizumab, first with rucaparib alone and then as a combination, in advanced gynaecological cancers and triple-negative breast cancer.\"},{\"question\":\"Who were the participants and what treatments did they receive?\",\"answer\":\"After dose identification, patients with PARPi-naive BRCA-mutated or HRD/loss-of-heterozygosity-high platinum-sensitive ovarian cancer or TNBC received rucaparib plus atezolizumab.\"},{\"question\":\"What adverse events were most common during the study?\",\"answer\":\"The most common adverse events included gastrointestinal effects, fatigue, liver enzyme elevations, and anaemia.\"}]","PARP inhibition with rucaparib alone followed by combination with atezolizumab - Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers | PDF",1790022024,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b340fdbf99629ab019705af170c569fb.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/78961a4caeea7fefc8a8bfb9a6aff563.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e24a1feb5dfd789fe22ebfb725067e6b.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a2194fddaebddf4d9b9961c57904bc70.webp",980,1301]